Striatal and Extra-striatal Mechanisms of Falling in Parkinson's Disease
Completed
Conditions studied: Parkinson's Disease
In brief
This research study will evaluate functions of memory, thinking, eye movements and walking and how these relate to the measurement of certain chemicals (acetylcholine and dopamine) in the brain using an imaging procedure called positron emission tomography (PET). You may know that the brain chemical dopamine, a "neurotransmitter" substance (a chemical messenger that nerve cells need to communicate with each other), is important for the brain to control movements and that the brain chemical acetylcholine may have functions related to mental concentration and attention. At the present time, the investigators have no clear information how these two chemicals in the brain of patients with Parkinson's disease are related to the risk of falling.
Key facts
- Study ID
- NCT00736671
- Run by
- University of Michigan
- People needed
- 88
- Starts
- 2006-07-01
- Expected to finish
- 2010-08-01
- Last updated by the study team
- 2016-03-04
Who can join
Age: 50 and older, up to 85. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Subjects considered for inclusion will be female or male subjects either currently enrolled or eligible for care at the VA aged 50-85 years, or community volunteers.
- The racial, gender and ethnic characteristics of the proposed subjects population reflect the demographics of the patient population of the VA. However, extra efforts will be made to recruit women and minorities (see table 5).
- Children will be excluded from the study.
- No exclusion criteria shall be based on race, ethnicity, gender, or asymptomatic HIV status.
You may not qualify if…
- Inability to stand or walk independently (i.e., patients in Hoehn and Yahr stage IV and V).
- Vertiginous disorder.
- Orthostatic hypotension or unstable cardiovascular disease at risk of syncope (drop in systolic blood pressure of > 20 mm Hg upon standing).
- History of stroke with focal cortical lesions.
- Cerebellar, myelopathic or significant radiculopathy syndrome.
- Diminished light perception in both eyes (< 20/40 corrected OU).
- Intracranial surgery.
- Subjects who have participated in other research protocols such that their cumulative radiation absorbed dose to whole body, gonads, bone marrow or lens of the eye would exceed 5 Rem, or dose to other body organs is more than 15 Rem in preceding 12 months.
- Pregnancy (beta-HCG test within 48 hours of PET study) or breastfeeding.
- Contra-indications to MRI.
Where it is running
- University of Michigan Functional Neuroimaging, Cognnitive and Mobility Laboratory — Ann Arbor, Michigan, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.